All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-05-28T08:35:34.000Z

Validity of the PBI-TOP tool for assessing patient goals and benefits of topical treatment in psoriasis

May 28, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriasis.

Bookmark this article

Topical treatment is often used as a first-line therapy for mild-to-moderate psoriasis and is available as cream, ointment, gel, foam, and lotion.1 Topical treatment works by reducing inflammation and reducing skin cell growth, but it can be less effective in patients with severe symptoms.1 Additionally, topical treatment can require increased effort and time to apply, which may result in low adherence.1

Here, we summarize a pilot validation study by Blome et al.1 published in British Journal of Dermatology assessing the feasibility of the Patient Benefit Index for Topical Treatment (PBI-TOP) tool in measuring the benefits of topical treatment in adult patients with psoriasis.1

Study design1

  • The following themes were identified through patient focus groups, patient interviews, open surveys, and literature searches:
    • Benefit of treatment
      • Effectiveness on symptoms
      • Effectiveness on quality of life
    • Characteristics of the preparation
  • Based on these themes, a pilot version of PBI-TOP was created, consisting of two sections:
    • Patient needs questionnaire (PNQ), where patients rate the importance of treatment goals in current/upcoming treatment
    • Patient benefit questionnaire (PBQ), where patient rate whether treatment goals have been achieved
  • Using both sections, a weighted score is calculated that shows treatment benefit for the patient.

Key findings1

  • A total of 154 patients completed the PNQ.
    • Of these, 121 also completed the PBQ and were included in treatment goal and benefit analysis in addition to assessing pilot validity.
  • Achievement of items, as assessed by PBQ, with the highest mean importance in the therapy goals and characteristics preferences in PNQ are shown in Figure 1. The percentage of patients who agreed they were quite/very important, were:
    • Less dry, cracked or scaly skin (86.8%)
    • Reduced redness or inflammation of the skin (86.0%)
    • No visible skin changes (78.5%)
    • No more itching (80.2%)
  • In the preparation characteristics preferences section of PBI-TOP, items with the highest mean importance in the PNQ, and percentage of patients who agreed they were quite/very important, were:
    • The preparation should be well tolerated (83.5%)
    • The preparation should not stain objects (71.9%)
    • The preparation should be easy to use (71.9%)
    • The preparation should be easy to dose (68.6%)
  • Items with the highest importance in the PNQ were not always highly achieved according to the PBQ (Figure 1). For example, ~60% or less of patients agreed that their therapy goals were quite or very much achieved after use of topical therapy, despite ~80% stating that this was quite/very important.

Figure 1. Achievement of the highest importance therapy goals and preparation characteristics (results of the PBQ)*

PBQ, patient benefit questionnaire.
*Data from Blome, et al.1

 

  • Table 1 shows the internal consistency of PBI-TOP scale and its correlation with convergent criteria.

Table 1. PBI-TOP scale internal consistency and correlation with convergent criteria*

PBI-TOP scale

Internal consistency

(Patients with PNQ data, n = 154)

Correlation with convergent criteria

(patients with PNQ and PBQ data, n = 121)

 

Cronbach’s α

DLQI

r (p value)

PASI

r (p value)

BSA

r (p value)

Overall effectiveness score

0.94

–0.41 (<0.001)

–0.32 (0.001)

–0.22 (0.046)

Effectiveness subscale

Symptoms

0.90

–0.41 (<0.001)

–0.27 (0.007)

–0.16 (0.155)

Quality of life

0.94

–0.32 (0.002)

–0.33 (0.002)

–0.23 (0.055)

Characteristics of the preparation score

0.90

–0.34 (0.001)

–0.19 (0.053)

–0.19 (0.089)

BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PNQ, patient needs questionnaire; PBI-TOP, Patient Benefit Index, version for topical treatment; PBQ, patient benefit questionnaire; r, correlation coefficient.
*Data from Blome, et al.1
Values in bold are statistically significant.

 

Key learnings 

  • The PBI-TOP tool demonstrated feasibility for use in patients with plaque psoriasis.
  • It can assist in personalizing topical treatment in patients with psoriasis, improving treatment adherence and outcomes.
  • The findings are limited by lack of patients with severe psoriasis and diverse patient groups; therefore, further research to address the applicability of PBI-TOP to other patients groups is warranted.
  • A long-term longitudinal study is ongoing to confirm the consistency and validity of PBI-TOP.

  1. Blome C, Hülswitt L, Meineke A, et al. Goals and benefits in topical treatment for psoriasis: development and pilot validation of a patient-reported outcomes tool, the Patient Benefit Index for Topical Treatment (PBI-TOP). Br J Dermatol. 2024; 190(5):701-711. DOI: 10.1093/bjd/ljad484

More about...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox